HbF Protein Induction Assay | Drug Screening for HemoglobinopathiesPROVIDED BY REACHBIO
A platform for screening drugs to treat Sickle Cell Disease and other Hemoglobinopathies
Hemoglobinopathies, including β-thalassemias (β-thal) and sickle cell disease (SCD), are a group of inherited blood disorders, most of which arise from mutations in the β-globin gene (HBB) cluster on chromosome 11 that encodes the β-subunit of hemoglobin (Hb). β-thal is characterized by a reduction in the production of adult Hb (HbA), whereas in SCD, the HbA produced is abnormal, causing the red blood cells (RBCs) to stiffen and adopt the “sickle” morphology. The result in many cases is severe anemia (very low RBC counts) and/or changes in the structure of the RBC, both of which compromise the ability of the hemoglobin to transport oxygen (O2) throughout the body.
Clinical severity of SCD, in particular, can be reduced by enhancing expression of the γ-globin gene (HBG) that encodes the γ-subunit of fetal hemoglobin (HbF), which is the main O2 transport protein in the fetus, and has a higher affinity for O2 than HbA. The approved drug, hydroxyurea (HU), is believed to increase HbF levels and is the current ‘standard of care’ drug for the treatment of SCD, but has had very limited success in treating β-thal, with only minor elevations in HbF achieved. Coupled with 30-50% of SCD patients being unresponsive to HU, the need for other good drug candidates remains high.
ReachBio’s HbF drug screening platform is a serum-free assay format where unaffected primary human bone marrow cells can be expanded in the presence of various cytokines in a two-step culture system:
Initial Stage – Synchronization of the cells
Second Stage – Induce differentiation along the erythroid (RBC) lineage
Read-Out is by Flow-Cytometry
Screening of new potential drug candidates may be performed alone or in conjunction with HU, which may have efficacy clinically in those with poor responses to HU.
Frontiers in Medicine
"The BACH1 Inhibitor ASP8731 Inhibits Inflammation and Vaso-occlusion and Induces Fetal Hemoglobin in Sickle Cell Disease"
John D. Belcher1, Selvaraj Nataraja2, Fuad Abdulla1, Ping Zhang1, Chunsheng Chen1, Julia Nguyen1, Conglin Ryan1, Maneet Singh2, Shipla Demes3, Lyndsay Olson2, Domi Stickens2, Jeff Stanwix2, Emer Clarke4, Yongzhao Huang4, Margaret Biddle2, and Gregory M. Vercellotti1 | 1 Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, United States | 2 Mitobridge Inc., Cambridge, MA, United States | 3 Astellas Pharma Global Development Inc., Northbrook, IL, United States | 4 ReachBio, Seattle, WA, United States
Blood | ASH
"A Novel BACH1 Inhibitor That Induces Fetal Hemoglobin in Treatment of Sickle Cell Disease"
Selva Nataraja, PhD, Maneet Singh, PhD, Shilpa Demes, PhD, Lyndsay Olson, Jeff Stanwix, Margaret Biddle, PhD, Emer Clarke, PhD, Yongzhao Huang, Julia Nguyen, Chunsheng Chen, PhD, Ping Zhang, PhD, Fuad Abdulla, Gregory M. Vercellotti, MD and John D Belcher, PhD, ASH 2022 Mitobridge, Cambridge, MA
Features & Advantages
- Allows for consistently induced HbF using HU as a positive control
- Serum-Free media allows for less batch to batch variability
- This method allows for the direct measurement of HbF protein compared to other indirect assays evaluating RNA transcript numbers.
- In addition to SCD applications, this assay can be used to measure induction of HbF for other hemoglobinopathies such as β-thalassemias.
- The assay allows for relatively high throughput formats (96 well plates)
For further details on our assay formats and representative data, please download the white paper.